Bucindolol's interaction with genes CYP2D6, ADRA2C, and ADRB1 affects its metabolism and effectiveness. Variability in CYP2D6 influences bucindolol's pharmacokinetics, impacting drug levels and patient responses, while genetic variants in ADRA2C and ADRB1 alter the functionality and expression of beta-adrenergic receptors, affecting the drug's impact on heart rate and myocardial contractility.